Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2023 03:00 ET | Source: Actimed Therapeutics

Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia

First Investigational New Drug (IND) approval for Actimed - a significant corporate milestoneApproval granted for the IMPACT programme – IMProving cancer cachexia with ACTAs...
August 22, 2023 04:00 ET | Source: Actimed Therapeutics

Actimed Therapeutics secures additional £4.75m funding in Series A extension round, almost doubling Series A proceeds

London, UK – 22 August 2023 Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
June 26, 2023 03:00 ET | Source: Actimed Therapeutics

Actimed Therapeutics closes over-subscribed Series A Financing Round of £5 million to advance clinical development of lead programme for cancer cachexia

London, UK – 26 June 2023. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other...